Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 207266; SB 207266; SB 207266A

Latest Information Update: 20 Apr 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Serodus
  • Class Heart failure therapies; Indoles; Oxazines; Small molecules
  • Mechanism of Action Serotonin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Heart failure
  • Discontinued Atrial fibrillation; Irritable bowel syndrome

Most Recent Events

  • 18 Jun 2008 Efficacy and adverse events data from a phase II trial in Heart failure released by Bio-Medisinsk Innovasjon
  • 31 Jul 2007 Bio-Medisinsk Innovasjon completes a phase II trial in heart failure in Denmark, Norway, and the UK
  • 02 Nov 2005 Phase-II clinical trials in Heart failure in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top